Börse Express – Molecular Devices opens the world’s second “Organoid Innovation Center” in Salzburg
Expansion of the global R&D center officially opened
Only three years after the opening of the Puch Knowledge Park near Hallein, the team at Molecular Devices Austria GmbH has every reason to celebrate. In the presence of dr Wilfried HaslauerGovernor of Salzburg, Suzanne MurphyPresident of Molecular Devices LLC , Joseph AtzlerManaging Director of Molecular Devices Austria GmbH, dr Martin AuerThe successfully completed expansion of the global R&D center was officially opened with the municipal council of Puch near Hallein and numerous guests from the life sciences industry.
The site, now expanded to 2700 m2, is located next to the headquarters in Silicon Valley, California world’s second Organoid Innovation Center/OIC. Molecular Devices’ OIC combines cutting-edge technologies with novel methods in 3D biology to solve key challenges of scaling complex 3D biology.
“The Organoid Innovation Center – Salzburg will prepare us for the future of science here in Puch near Salzburg, a growing business and research center that uses cutting-edge technologies and innovative collaborations,” So Salzburg’s Governor Dr. Wilfred Haslauer. “I would like to thank Molecular Devices and the company’s management team for their continued commitment to investing in local talent and the local economy.”
“With leading companies like Molecular Devices at the Urstein Knowledge Park – a growing campus of industry innovators – we are driving next-generation life science research in the region, which is being positively heralded around the world,” he said Martin Auer, municipal councilor of Puch near Hallein.
Similar to the Organoid Innovation Center in San Jose, California, the new Salzburg location will allow life scientists to experience firsthand how automated, end-to-end workflow solutions can help alleviate pain points in their own labs.
“In Salzburg – the hub of our global R&D activities – we will showcase the cutting-edge technologies, applications and workflows designed to help life science researchers successfully advance more drug candidates through clinical trials.”So Susan Murphy, President of Molecular Devices. “With expanded capabilities, we will continue to drive the development of integrated, future-proof solutions to advance scientific discovery together with our European customers and partners.”
Successful expansion in Austria is usually
Molecular Devices Austria has been on a successful course of expansion since it was founded. In the last 3 years alone, the number of employees has increased from 50 in 2019 to 78 highly qualified specialists from currently 20 nations. The sales of the life science technology company amounted to €38.0 million in 2021 (2019: €24.1 million). Since 2019, investments of over €9 million have been made for initial OIC projects and a further €10 million in microplate detection. The building expansion has a total cost of €1.3 million.
About MOLECULAR DEVICES LLC
Headquartered in San Jose, California, Molecular Devices LLC is a global life science technology innovator with offices worldwide and 1,200 employees supporting scientists in more than 21 countries. Molecular Devices is an independent company and since 2010 has been part of the listed Danaher Corporation, which, with 69,000 employees and sales of USD 29.45 billion in 2021, is one of the 500 top-selling companies in the world according to the US business magazine Fortune.
Integrated hardware and software solutions enable automated workflows for any research application, helping scientists advance their discoveries, resulting in faster diagnoses and safer therapies for patients. Whether cell line development, 3D biology, drug screening or a combination of all three areas, Molecular Devices develops complete solutions for every application – for academic, pharmaceutical, government and biotechnology customers.